Haleos Labs Limited (HALEOSLABS.NS)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | INR m | 2,647 | 3,473 | 3,125 | 2,996 | 3,368 | 3,338 | 3,242 | - |
| Operating profit | INR m | 292 | 250 | ||||||
| Net profit | INR m | 136 | 253 | 115 | 91 | 201 | 173 | 158 | - |
| EPS reported | INR | 57.26 | 52.27 | ||||||
| Operating cashflow per share | INR | 115.7 | 151.4 | ||||||
| Capex per share | INR | 191.4 | 64.60 | ||||||
| FCF per share | INR | -75.74 | 86.77 | ||||||
| Free cash flow | INR m | -229 | 262 | ||||||
| Net debt | INR m | 1,074 | 1,065 | ||||||
| Book value equity | INR m | 2,135 | 2,135 | ||||||
| Book value per share | INR | 706.4 | 706.3 | ||||||
| Number of shares | m | 3.02 | 3.02 | ||||||
| DPS (TTM paid) | INR | 1.50 | 3.00 |
Financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 20.85 | 27.77 | ||||||
| P/B LTM | x | 1.60 | 1.60 | ||||||
| P/S LTM | x | 1.03 | 1.06 | ||||||
| P/FCF LTM | x | -14.95 | 13.05 | ||||||
| EV/EBITDA LTM | x | 9.59 | 10.37 | ||||||
| EV/Sales LTM | x | 1.41 | 1.69 | ||||||
| Earnings Yield LTM | % | +4.80% | +3.60% | ||||||
| FCF Yield | % | -6.69% | +7.66% | ||||||
| Quality | |||||||||
| ROE | % | +8.11% | +7.69% | ||||||
| ROIC | % | +5.77% | +4.93% | ||||||
| Operating margin | % | +8.75% | +7.71% | ||||||
| Gross margin | % | +14.38% | +19.82% | ||||||
| FCF/Sales | % | -6.86% | +8.09% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -13.91% | -21.41% | ||||||
| Sales Growth YoY | % | -0.89% | -3.73% | ||||||
| Net Income Growth YoY | % | -13.91% | -21.42% | ||||||
| FCF Growth | % | - | +40.24% | ||||||
| Operating Profit Growth | % | -3.05% | -16.99% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +0.13% | +0.10% | ||||||
| Dividend Growth | % | 0.00% | +100.00% | ||||||
| Payout Ratio | % | +2.62% | +2.62% | ||||||
| FCF/Debt | x | -0.21 | 0.24 | ||||||
| Net Debt/EBITDA | x | 2.42 | 2.62 | ||||||
| EBIT/Net interest | x | 4.53 | 3.86 | ||||||
| Net debt/market cap | % | +30.40% | +24.72% | ||||||
| Net debt/Equity | x | 0.50 | 0.50 | ||||||
| Gross debt/equity | x | 0.52 | 0.52 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Haleos Labs Limited, an Indian-based pharmaceutical enterprise, specializes in the production of crucial active pharmaceutical ingredients (APIs) and intermediate compounds. Their extensive portfolio encompasses a wide array of therapeutic applications, providing treatments for conditions such as ulcers, migraines, hypertension, and erectile dysfunction. Additionally, the company develops products for cancer, fungal infections, obesity, nausea, depression, parasitic infestations, various infectious diseases, gout, convulsions, viral ailments, and anesthesia. They also supply ingredients for antihistamines, diuretics, hair loss treatments, and ophthalmic preparations. A significant portion of their manufactured goods is destined for international markets. Established in 1990 and headquartered in Hyderabad, India, the firm was formerly known as SMS Lifesciences India Limited and is scheduled to officially adopt its current name, Haleos Labs Limited, in August 2025.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Haleos Labs Limited (HALEOSLABS.NS)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Haleos Labs Limited, an Indian-based pharmaceutical enterprise, specializes in the production of crucial active pharmaceutical ingredients (APIs) and intermediate compounds. Their extensive portfolio encompasses a wide array of therapeutic applications, providing treatments for conditions such as ulcers, migraines, hypertension, and erectile dysfunction. Additionally, the company develops products for cancer, fungal infections, obesity, nausea, depression, parasitic infestations, various infectious diseases, gout, convulsions, viral ailments, and anesthesia. They also supply ingredients for antihistamines, diuretics, hair loss treatments, and ophthalmic preparations. A significant portion of their manufactured goods is destined for international markets. Established in 1990 and headquartered in Hyderabad, India, the firm was formerly known as SMS Lifesciences India Limited and is scheduled to officially adopt its current name, Haleos Labs Limited, in August 2025.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free